๊ธˆ์œต
๊ธˆ์œต
ํ™ˆB1MR34 โ€ข BVMF
๋ฐ”์ด์˜ค๋งˆ๋ฆฐ ์ œ์•ฝ
R$167.01
1์›” 2์ผ, PM 9์‹œ 0๋ถ„ 0์ดˆ GMT-3 · BRL · BVMF · ๋ฉด์ฑ…์กฐํ•ญ
์ฃผ์‹BR ์ƒ์žฅ ์ฆ๊ถŒ๋ฏธ๊ตญ์— ๋ณธ์‚ฌ ์†Œ์žฌ
์ „์ผ ์ข…๊ฐ€
R$167.01
52์ฃผ ๋ณ€๋™ํญ
R$139.16 - R$208.72
์‹œ๊ฐ€์ด์•ก
114.21์–ต USD
ํ‰๊ท  ๊ฑฐ๋ž˜๋Ÿ‰
118.00
์ฃผ๊ฐ€์ˆ˜์ต๋ฅ 
-
๋ฐฐ๋‹น์ˆ˜์ต๋ฅ 
-
๋‰ด์Šค
FOLD
0.21%
BMRN
0.034%
์žฌ๋ฌด
์†์ต๊ณ„์‚ฐ์„œ
์ˆ˜์ต
์ˆœ์ด์ต
(USD)2025๋…„ 9์›”์ „๋…„๋Œ€๋น„ ๋ณ€๋™
์ˆ˜์ต
7.76์–ต4.08%
์šด์˜๋น„
6.83์–ต53.98%
์ˆœ์ด์ต
-3074.40๋งŒ-128.98%
์ˆœ์ด์ต๋ฅ 
-3.96-127.85%
์ฃผ๋‹น ์ˆ˜์ต
0.12-86.81%
EBITDA
-2820.50๋งŒ-121.22%
์œ ํšจ ์„ธ์œจ
-16.79%โ€”
์ด์ž์‚ฐ
์ด๋ถ€์ฑ„
(USD)2025๋…„ 9์›”์ „๋…„๋Œ€๋น„ ๋ณ€๋™
ํ˜„๊ธˆ ๋ฐ ๋‹จ๊ธฐ ํˆฌ์ž
14.78์–ต58.83%
์ด์ž์‚ฐ
76.15์–ต11.15%
์ด๋ถ€์ฑ„
15.58์–ต8.37%
์ด์ž๊ธฐ์ž๋ณธ
60.57์–ตโ€”
๋ฐœํ–‰ ์ฃผ์‹
1.92์–ตโ€”
์ฃผ๊ฐ€์ˆœ์ž์‚ฐ๋น„์œจ
5.30โ€”
์ด์ž์‚ฐ์ด์ต๋ฅ 
-1.55%โ€”
์ž๋ณธ์ด์ต๋ฅ 
-1.76%โ€”
์ˆœํ˜„๊ธˆํ๋ฆ„
(USD)2025๋…„ 9์›”์ „๋…„๋Œ€๋น„ ๋ณ€๋™
์ˆœ์ด์ต
-3074.40๋งŒ-128.98%
์˜์—… ํ˜„๊ธˆ ํ๋ฆ„
3.69์–ต66.46%
ํˆฌ์ž ํ˜„๊ธˆ ํ๋ฆ„
-3.31์–ต-1,948.42%
์ž๊ธˆ ์กฐ๋‹ฌ ํ˜„๊ธˆ ํ๋ฆ„
-216.90๋งŒ99.57%
์ˆœํ˜„๊ธˆํ๋ฆ„
3629.20๋งŒ112.23%
์ž‰์—ฌ ํ˜„๊ธˆ ํ๋ฆ„
1.14์–ต-31.13%
์ •๋ณด
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
์„ค๋ฆฝ
3์›” 1997
์›น์‚ฌ์ดํŠธ
์ง์› ์ˆ˜
3,040
๋” ์•Œ์•„๋ณด๊ธฐ
๊ด€์‹ฌ ์žˆ์„ ๋งŒํ•œ ์ฃผ์‹ ์ •๋ณด
์ด ๋ชฉ๋ก์€ ์ตœ๊ทผ ๊ฒ€์ƒ‰์–ด, ํŒ”๋กœ์šฐํ•œ ์ฆ๊ถŒ, ๊ธฐํƒ€ ํ™œ๋™์„ ๊ธฐ๋ฐ˜์œผ๋กœ ์ƒ์„ฑ๋˜์—ˆ์Šต๋‹ˆ๋‹ค. ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ

๋ชจ๋“  ๋ฐ์ดํ„ฐ์™€ ์ •๋ณด๋Š” ๊ฐœ์ธ์—๊ฒŒ ์ •๋ณด๋ฅผ ์ œ๊ณตํ•˜๋Š” ๋ชฉ์ ์œผ๋กœ '์žˆ๋Š” ๊ทธ๋Œ€๋กœ' ์ œ๊ณต๋˜๋ฉฐ ๊ธˆ์œต ์ž๋ฌธ์ด๋‚˜ ๊ฑฐ๋ž˜ ๋˜๋Š” ํˆฌ์ž, ์„ธ๊ธˆ, ๋ฒ•๋ฅ , ํšŒ๊ณ„ ๋“ฑ์— ๊ด€ํ•œ ์ž๋ฌธ์„ ์˜๋„ํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค. Google์€ ํˆฌ์ž ์ž๋ฌธ๊ฐ€๊ฐ€ ์•„๋‹ˆ๋ฉฐ ์ด ๋ชฉ๋ก์— ํฌํ•จ๋œ ํšŒ์‚ฌ ๋˜๋Š” ์ด๋Ÿฌํ•œ ํšŒ์‚ฌ์—์„œ ๋ฐœํ–‰ํ•œ ์ฆ๊ถŒ๊ณผ ๊ด€๋ จํ•˜์—ฌ ๊ฒฌํ•ด, ์ถ”์ฒœ ์˜์‚ฌ ๋˜๋Š” ์˜๊ฒฌ์„ ๋ฐํžˆ์ง€ ์•Š์Šต๋‹ˆ๋‹ค. ๊ฑฐ๋ž˜๋ฅผ ์ฒด๊ฒฐํ•˜๊ธฐ ์ „์— ์ค‘๊ฐœ์ธ์ด๋‚˜ ๊ธˆ์œต ๋Œ€๋ฆฌ์ธ์—๊ฒŒ ๋ฌธ์˜ํ•˜์—ฌ ๊ฐ€๊ฒฉ์„ ํ™•์ธํ•˜์„ธ์š”. ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ
ํ•จ๊ป˜ ๊ฒ€์ƒ‰ํ•œ ํ•ญ๋ชฉ
๊ฒ€์ƒ‰
๊ฒ€์ƒ‰์–ด ์ง€์šฐ๊ธฐ
๊ฒ€์ƒ‰ ๋‹ซ๊ธฐ
Google ์•ฑ
๊ธฐ๋ณธ ๋ฉ”๋‰ด